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Chloroquine (CQ)–resistant Plasmodium vivax malaria was first reported 12 years ago,
nearly 30 years after the recognition of CQ-resistant P. falciparum. Loss of CQ efficacy now
poses a severe problem for the prevention and treatment of both diseases. Mutations in a
digestive vacuole protein encoded by a 13-exon gene, pfcrt, were shown recently to have a
central role in the CQ resistance (CQR) of P. falciparum. Whether mutations in pfcrt orthologues of other Plasmodium species are involved in CQR remains an open question. This
report describes pfcrt homologues from P. vivax, P. knowlesi, P. berghei, and Dictyostelium
discoideum. Synteny between the P. falciparum and P. vivax genes is demonstrated. However,
a survey of patient isolates and monkey-adapted lines has shown no association between in
vivo CQR and codon mutations in the P. vivax gene. This is evidence that the molecular events
underlying P. vivax CQR differ from those in P. falciparum.

In malaria campaigns, the morbidity and mortality of Plasmodium falciparum malaria in Africa is often emphasized, whereas
the global impact of the less deadly malaria caused by P. vivax
is overshadowed. Although P. vivax malaria rarely is fatal, it is,
nevertheless, a debilitating disease with tremendous impact on
the quality of life and economic productivity. Estimates of the
annual number of P. vivax cases range from 75 to 90 million,
with most occurring outside Africa. Chloroquine (CQ) has been
the drug of choice for eliminating P. vivax blood stages, but
resistance has been an increasing problem since it was first re-
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ported in Papua New Guinea in 1989 [1] and Indonesia in 1991
[2, 3]. Field trials in Papua (Indonesian New Guinea, formerly
known as Irian Jaya) showed recrudescence in 22% of patients
with P. vivax after treatment with CQ [4]. CQ resistance (CQR)
also was found in 14% of P. vivax infections in an island population off the coast of northwestern Sumatra [5]. The geographic
distribution of CQ-resistant P. vivax has extended more recently
to India [6, 7], Myanmar [8, 9], and, in the Western Hemisphere,
to Guyana [10] and Brazil [11].
Despite comparable use of CQ against P. vivax and P. falciparum malaria throughout the second half of the 20th century,
the emergence of CQR in P. vivax 3 decades after that of P.
falciparum [12, 13] and the unique recurrence profile of CQresistant P. vivax, compared with that of CQ-resistant P. falciparum in vivo [14], suggest the possibility of different resistance mechanisms between the 2 species. A gene (pfcrt) with a
central role in the CQR of P. falciparum has been described
recently [15]. Point mutations in the encoded PfCRT protein
were found to associate completely with the in vitro laboratory
measurements of CQR in P. falciparum lines from Asia, Africa,
and South America. The importance of these mutations was
reinforced further by genetic transformation results and by a
West African study that showed that PfCRT K76T and certain
other accompanying amino acid changes were selected in 100%
of patients in whom treatment failed, compared with the baseline prevalence of ∼40% in the overall population [16]. PfCRT
is a transmembrane protein that localizes to the parasite digestive vacuole, the site of CQ action [17]. Increased acidification of this vacuole associates with PfCRT mutations and
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CQR [15]. Therefore, the question arises as to whether mutations in an orthologue of pfcrt may be similarly responsible for
CQR in P. vivax.
The genus Plasmodium comprises deeply branched clades of
what are considered to be 3 major evolutionary groups. Representative members of these groups include the following: P.
falciparum, the closely related ape parasite P. reichenowi, and
avian malaria parasites, such as P. gallinaceum; P. vivax and
monkey malarias, such as P. knowlesi; and rodent malaria parasites, such as P. berghei, P. chabaudi, and P. yoelii [18]. Major
differences in host specificity and disease manifestations occur
among species of these groups, as do dramatic variations in
genome composition and codon usage [19].
Here we describe pfcrt orthologues from P. vivax, P. knowlesi,
and P. berghei and a pfcrt homologue from the slime mold
Dictyostelium discoideum, and present evidence for different
mechanisms of CQR in P. falciparum and P. vivax.

Materials and Methods
Preparation of polymerase chain reaction (PCR) templates from
blood samples. P. vivax–infected monkey red blood cells were
lysed and washed with Tris-EDTA buffer (10 mM Tris-HCl and 1
mM disodium EDTA [pH 7.6]) and RCLB solution (1 M sucrose,
10 mM Tris-HCl [pH 7.6], 5 mM MgCl2, and 1% [vol/vol] Triton
X100 in H2O). Pellets were resuspended in DSP (20 mM Tris-HCl
[pH 7.6], 50 mM KCl, 2.5 mM MgCl2, 1 g/L proteinase K, and
0.5% Tween 20) and were incubated at 56⬚C for 2 h and then at
90⬚C for 10 min. Two microliters of this solution was used for each
PCR assay. Dried blood samples from transmigrated Javanese patients infected with P. vivax were sectioned into 3-mm2 pieces and
were fixed with methanol for 15 min at room temperature. After
drying, the pieces were soaked in 50 mL of H2O, and 5 mL of the
recovered solution was used for each PCR reaction.
Isolation of pfcrt homologues from D. discoideum, P. knowlesi,
P. vivax, and P. berghei. PCR amplifications were performed
using standard reagents and 50 ng of genomic DNA or 0.1 mL of
heat-denatured DNA from cDNA or genomic DNA libraries as
template. Extension temperatures were 64⬚C for P. knowlesi DNA
and 72⬚C for P. vivax DNA. The D. discoideum clone ssa662
(GenBank accession nos. AU076370 and C83926) was identified
by the basic local alignment search tool (BLAST) screening of
National Center for Biotechnology Information (NCBI) databases
(http://www.ncbi.nlm.nih.gov/BLAST) and was obtained from
Hideko Urushihara (Institute of Biological Sciences, University of
Tsukuba, Japan) for sequencing.
PCR amplifications with 4 different primer pairs were used to
identify the P. knowlesi orthologue pkcg10. PCR primer pairs BF92
(5-GCT TTT CAA ACA TGA CAA GGG-3) and BB103C (5TTG CTG GAC CTT GTA TAC AAC TAA C-3), which were
designed from exons 5 and 10 of pfcrt, respectively, amplified a 0.5kb cDNA fragment encoding a central part of pkcg10 from an
erythrocytic-stage P. knowlesi lgt11 cDNA library [20]. Primer
KB1 (5-CCC AAT CCA CAG TTC TCC ACA ATA G-3), which
was designed from the sequence of the first product, and primer
AF12B (5-GGT AAC TAT AGT TTT GTA ACA TCC G-3),
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which was designed from pfcrt exon 2, amplified a further 0.6-kb
cDNA fragment from pkcg10. Primer K4B7 (5-GAA TGT TTC
CAG TGG TTC TTG TGA GG-3), which was designed from the
aforementioned 0.6-kb cDNA fragment, and the vector-specific
primer GT11F3 (5-TAT GGG GAT TGG TGG CGA CGA CTC
C-3) amplified the 5 untranslated sequence of the P. knowlesi orthologue. Primer KAF22 (5-GCG ACG ATT GTG AAG GAG
CAT GG-3), which was designed from the first (0.5 kb) fragment,
and the vector-specific primer GT11F3 (5-TAT GGG GAT TGG
TGG CGA CGA CTC C-3) amplified the 3 untranslated region
(UTR) of pkcg10.
PCR amplifications and genomic library screening were used to
identify the P. vivax orthologue pvcg10. Primers KF4 (5-CCC TTC
TCG GAA ATC GGA ACG-3) and KB2 (5-CAA TCG TCG
CAC ATC TTG G-3) were designed from the pkcg10 sequence
and were used to amplify a 0.3-kb genomic DNA fragment spanning exons 8 and 9 from DNA of P. vivax Salvador I (Sal I) line.
This fragment was used to probe and to identify a 6-kb HindIII
insert from a P. vivax Salvador I genomic DNA library [21]. The
6-kb DNA insert spanned exons 6–14 and the 3 UTR of the P.
vivax orthologue. Primers K6F (5-GAT GAA CGT TAC CGG
GAG TTG G-3) and K6B45 (5-GCA ATG ATA ACT GAG CAG
GCG TC-3) were designed from the P. knowlesi pkcg10 sequence
and were used to amplify genomic sequence containing exons 1–3
of pvcg10. Primers V2F20 (5-GCA GGA GAG ACA CCG AAA
C-3) and VK2B4 (5-ATC GGA AGC ATC AGG CAG GAG G3) were used to amplify a fragment containing exons 3–6 of pvcg10.
Primer VB2 (5-TGC GTC TCG GAG GTT ACA AAG C-3) and
the M13 forward primer M13F1 (5-CGC CAG GGT TTT CCC
AGT CAC GAC-3) were used to amplify a fragment extending
into the 5 UTR of pvcg10.
Expressed sequence tag (EST) and genome survey sequence deposits corresponding to P. berghei orthologue pbcg10 were identified by BLAST screening of the University of Florida Plasmodium
berghei Gene Sequence Tag Project via the NCBI Malaria Genetics
and Genomics World Wide Web pages (http://www.ncbi.nlm.nih
.gov/Malaria/). Clones UFL_244PbC09, UFL_056PbB12, and
UFL_053PbC06 were obtained and sequenced to obtain the full
open-reading frame (ORF) of pbcg10. Sequence data from this
work are deposited in the DNA DataBank of Japan, European
Molecular Biology Laboratory, and GenBank databases under accession numbers AF314645–AF314649 and AF317500.
Identification of P. vivax orthologues pvcg9, pvcg1, and pvcg4.
The 6-kb P. vivax genomic DNA clone that contained exons 6–14
and the 3 UTR of pvcg10 was sequenced further, and ORFs of
pvcg9 and pvcg1 were identified. Oligonucleotide primers 5-TGG
ACA ACC ACT CCC TGG ACT CTA CCT-3 and 5-GCT TTT
GCT CAT TTT TCT GCC-3, which originally were designed to
amplify isoleucine tRNA synthase from P. vivax, amplified a 1.1kb fragment from P. vivax North Korea genomic DNA. The fragment was cloned into vector pCR2.1 (Invitrogen), was sequenced
from both ends, using primer sites in the vector, and was found by
database searches to have homology to pfcg4. Probes for pvcg1
were amplified by use of primer pairs VCG1F (5-CCA TAC ACC
AAA CTG GAC TCG G-3) and VCG1B (5-GCT AAA CAC
GCA ACT GCT GAT GAG-3), and probes for pvcg4 were amplified by use of primer pairs 1474 (5-ATG TCC GTG CTC GGA
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ATC GAC ATC GGA AAT GAC-3) and 1475 (5-CTC TAC CTG
GTA GCC CAG GTA GTT ATG CTC-3).
Pulsed-field gel electrophoresis (PFGE). Yeast harboring yeast
artificial chromosome (YAC) A8 [22] was incubated in a sorbitol
solution (0.1 M disodium EDTA, 0.1 M Tris–HCl [pH 8.0], and 0.9
M sorbitol in H2O) with 28 mM b-mercaptoethanol and 1000 U/mL
of Lyticase (Sigma). The resulting spheroplasts were embedded in
0.5% (wt/vol) agarose (SeaPlaque; FMC BioProducts), and the
blocks were treated with EPS (1% wt/vol sodium N-lauroylsarcosine
and 2 mg/mL of proteinase K in 0.5 M disodium EDTA) at 37⬚C
for 48 h. Chromosomes were separated for 48 h by PFGE (14⬚C,
180 V, 0.2 A, switching times ramped from 10 s to 40 s) in 0.8%
agarose gel with 0.5⫻ TBE buffer (10⫻ TBE buffer is composed of
108 g of Tris base, 54 g of boric acid, and 8.35 g of disodium EDTA
per liter of H2O) and were blotted onto nylon membrane.
Papua case study design. Javanese transmigrants residing in
the hyperendemic Bonggo District of coastal Papua, self-reported
to a research team–operated clinic with complaints of symptoms
consistent with malaria. All diagnoses were made by examination
of Giemsa-stained blood films by expert microscopists, using standard light microscopy. Patient assessment, treatment, and followup were carried out as described elsewhere [23]. P. vivax parasites
were classified as CQ sensitive or resistant, according to the results
of a standard 28-day in vivo drug test, which takes into account
whole blood levels of CQ and desethylchloroquine at the time of
recurrence of parasitemia [14].

Results
Conserved features of a novel family of transporter protein
homologues in P. vivax, P. knowlesi, P. berghei, and D. discoideum. Investigation of homologues from other organisms
can reveal regions of the pfcrt gene and its PfCRT product that
have been maintained in evolution by structural and functional
constraints. Therefore, we used in silico sequence analysis and
targeted PCR screening with codon-adjusted primers to identify
pfcrt orthologues in representatives of 3 deeply branched evolutionary lineages of the genus Plasmodium and a more distant
homologue from D. discoideum. Sequence database searches
using BLAST programs [24, 25] gave a significant match between part of the P. falciparum pfcrt coding sequence and 2
partial cDNA sequences from the D. discoideum cDNA project
(GenBank accession nos. AU07268 and C83926) [26]. Inspection of the amino acid sequence encoded by these 2 ESTs indicated potential similarities to the structure of the PfCRT Cterminal region. Therefore, the full-length coding region from
one of the corresponding D. discoideum cDNA clones, ssa662,
was determined. The predicted SSA662 amino acid sequence
from this coding region demonstrated homology with PfCRT
along its entire length (figure 1).
To identify pfcrt homologues in representative species of the
3 evolutionary branches of Plasmodium, we first used codonadjusted primers from the pfcrt / ssa662 alignment to amplify
fragments from a P. knowlesi blood-stage cDNA library. Analysis of these cDNA fragments identified an ORF encoding a
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pfcrt homologue, which we termed pkcg10 (figure 1). Conserved
regions of this homologue, in addition to pfcrt, then were employed to obtain a complete genomic sequence of a pfcrt homologue of P. vivax. Initial amplifications of genomic DNA
produced probes that were used to screen a P. vivax genomic
DNA library. Analysis of these fragments identified the full P.
vivax coding sequence of a pfcrt homologue, which we term
pvcg10. Partial sequence of a pfcrt homologue of the rodent
malaria parasite P. berghei, pbcg10, was identified through a
search of the University of Florida Gene Sequence Tag Project
databases [28]. Representative cDNA and genomic clones were
obtained and sequenced in their entirety, to yield the complete
pbcg10 coding sequence (figure 1).
Comparative alignments of the amino acid sequences translated from pfcrt, pvcg10, pkcg10, pbcg10, and D. discoideum
clone ssa622 show striking conservation in overall composition
and structural features (figure 1). Consensus prediction indicates that these proteins have 10 transmembrane segments,
which are conserved in spacing and orientation. The transmembrane helix-end motifs are consistent with a model in
which the N- and C-termini of the proteins are located on the
cytoplasmic side of the membrane. Motif searches showed no
evidence for the presence of a typical signal sequence or other
recognizable feature, such as an ATP-binding motif. These
properties suggest that PfCRT, PvCG10, PkCG10, PbCG10,
and SSA662 are members of a previously undescribed family
of transporter proteins.
Striking conservation in the positions of intron-exon junctions inferred from the genomic sequences of pfcrt and pvcg10
also was apparent. Figure 2 shows a schematic diagram of the
arrangement of the coding regions in the exons of pfcrt and
pvcg10. The pvcg10 coding sequences extend across 14 exons,
which range from 45 to 266 bp and are interrupted by 13 introns
ranging from 114 to 491 bp. The splice sites of 12 of 13 introns
in pvcg10 are found at positions identical to those of the 12
introns in pfcrt. The additional intron in pvcg10 has no counterpart in pfcrt and splits the reading frame that corresponds to
pfcrt exon 3. The compositional properties of the introns differ
dramatically between pfcrt and pvcg10, which is consistent with
the genome-wide difference among the G⫹C contents of P.
falciparum (∼18% G⫹C) and P. vivax (∼45% G⫹C).
Synteny between P. falciparum and P. vivax pfcrt orthologues
and nearby genes. Comparative sequence analysis demonstrated a close relationship between pfcrt and pvcg10; however,
further evidence that these genes are orthologues was desirable.
Therefore, syntenic relationships were investigated between the
genes neighboring pfcrt and pvcg10 in the P. falciparum and P.
vivax chromosomes. First, partial sequencing of the 6-kb P.
vivax genomic library clone, from which exons 6–14 of pvcg10
were identified, was used to identify 2 ORFs 4-kb downstream
of pvcg10, in the same position as the P. falciparum pfcg9 and
pfcg1 genes relative to pfcrt (figure 2). Translation of the pvcg9
and pvcg1 ORFs yielded amino acid sequences with 32% and
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Figure 1. Comparison of the predicted sequences for PfCRT (clone HB3) and its homologues PvCG10 (Salvador I), PkCG10, PbCG10, and
Dictyostelium discoideum (D.disc) SSA662. Matching amino acids across all species are shaded darkly, whereas matching amino acids in ⭓3 species
are shaded lightly. Lines over sequences indicate putative transmembrane segments predicted by TMHMM [27].

39% amino acid identity to the predicted PfCG9 and PfCG1
sequences, respectively (data not shown). A third partial sequence of a P. vivax gene, pvcg4, also was recognized in a
serendipitous product in separate PCR amplifications of genomic DNA. The amino acid translation from pvcg4 showed
75% identity with the predicted sequence from pfcg4 over 105
residues (data not shown). This relationship provided another
probe to investigate synteny, since pfcg4 is located ∼5 kb from
pfcrt on P. falciparum chromosome 7 [15].
To confirm synteny in the organization of these P. vivax and
P. falciparum genes, a YAC library containing large inserts of P.
vivax DNA [22] was screened with PCR primer pairs specific for
pvcg10. A clone identified by this screen, YAC A8, was found
to harbor a 350-kb insert that hybridized to the separate pvcg10,
pvcg4, and pvcg1 probes (figure 3). These results established the
presence of syntenic relationships upstream and downstream of
pfcrt and pvcg10. Given this, their close homology, and the almost
identical intron-exon organization of these genes, we conclude

that pfcrt and pvcg10 are true orthologues within this family of
transporter genes.
PvCG10 mutations are not associated with CQR in monkeyadapted P. vivax isolates. In contrast to the case for P. falciparum, P. vivax cannot be consistently maintained in vitro [29].
Practicable in vitro drug susceptibility assays on cultivated parasite lines are therefore not possible. Instead, the resistance status
of the parasite is usually determined from patients’ clinical responses or from in vivo responses of adapted lines maintained
in monkeys or chimpanzees. Therefore, we studied 14 isolates of
P. vivax maintained at the Centers for Disease Control and Prevention (CDC) by serial passage in monkeys (table 1).
Of the 14 monkey-adapted strains, 3 were CQ resistant. One
strain, AMRU-1, which originally was isolated from an Australian serviceman stationed in Papua and for whom CQ treatment failed [1], was adapted to growth in Aotus monkeys [44]
and consistently failed to clear at doses ⭐30 mg/kg of CQ
administered over 3 days [31]. The second strain, Indonesia
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Figure 2. Intron-exon organization of pfcrt and pvcg10 and surrounding genes. A, Gene structure of a part of the 38-kb Plasmodium falciparum
chromosome 7 region (GenBank accession no. AF030694) [15] showing the relative positions of pfcg4, pfcg3, pfcrt, pfcg9, and pfcg1. B, Gene structure
of Plasmodium vivax DNA containing orthologues pvcg10, pvcg9, and pvcg1. Boxes indicate exons, and arrows indicate gene direction. Note that the
organization of pfcrt, pfcg9, and pfcg1 is comparable with that of pvcg10, pfcg9, and pvcg1, which provides evidence that pvcg10 is an orthologue of
pfcrt. The probable location of pvcg4 also is shown. Coding directions indicated by the arrows are assumed and have not been verified by directional
mapping.

XIX/CDC P. vivax, was isolated from patients in Papua and
was resistant to 15 mg/kg of CQ administered over 3 days [30].
The third strain, Indonesia I/CDC, was isolated from a patient
on the island of Nias. CQ treatment [3] of the patient was
unsuccessful, and the strain was adapted to growth in Aotus
monkeys, in whom it was found to be resistant to treatment
with 15 mg/kg of CQ given as a single dose [32]. The resistant
phenotypes of these 3 strains are in direct contrast to the sensitive phenotypes of the 11 strains listed in table 1, which were
collected before successful CQ treatment of patients.
The pvcg10 coding sequences of these isolates were compared.
The 14 exons of 2 CQ-resistant (Indonesia XIX and AMRU1) and 2 CQ-sensitive (Chesson and Salvador I) strains were
sequenced in their entirety. The only nonsynonymous point
mutations identified were at amino acid positions 34 and 38
(Chesson) and 384 (AMRU-1). Therefore, exons containing
codons 34 and 38 were sequenced in the 10 remaining isolates.
These exons showed identical pvcg10 haplotypes (table 2).
These results demonstrate a lack of association between codon
mutations in pvcg10 and in vivo CQ susceptibility of the P.
vivax monkey-adapted lines.
PvCG10 mutations are not associated with CQR in P. vivax
patient isolates from Papua. To test further our PvCG10 mutation findings, we sequenced pvcg10 alleles of P. vivax obtained
from patients who lived in an endemic area and for whom CQ
treatment in vivo had failed. Stringent criteria are necessary to
make definitive pronouncements of in vivo resistance to therapeutic levels of CQ. These criteria include supervision of the
appropriate dose of CQ, monitoring of parasitemia, and the
demonstration of parasites in the presence of CQ blood levels
that are greater than the minimally effective concentration (100
ng/mL for P. vivax) derived from CQ-sensitive strains of this
parasite [14]. Using these criteria, 8 P. vivax isolates were obtained from Papuan patients with CQ-sensitive or -resistant
infections. Four of these infections were classified as clinically
resistant, 3 as clinically sensitive, and 1 as probably resistant,
because the measured blood level of 85 ng/mL was below the
formal cutoff of 100 ng/mL (table 3).

The sequences of all exons of pvcg10 were determined for 2
resistant (CL002 and CL004), 1 sensitive (CL007), and the 1 probably resistant sample (CL003). No new nonsynonymous mutations
were found in these sequences. In light of these results, the re-

Figure 3. Hybridization of pvcg4, pvcg10, and pvcg1 probes to Plasmodium vivax yeast artificial chromosome (YAC) A8 separated by pulsedfield gel electrophoresis. YAC A2 (150 kb) and YAC A8 (350 kb) are
loaded on odd and even lanes, respectively. Gel was stained with ethidium
bromide (lanes 1 and 2) and was blotted onto nylon membrane for
probing with pvcg4 (lanes 3 and 4), pvcg10 (lanes 5 and 6), and pvcg1
(lanes 7 and 8).
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Table 1. Origin, isolation, and chloroquine (CQ) response data for 14 lines of monkey-adapted Plasmodium vivax.
Line

Country

Isolation and monkey adaptation

Indonesia XIX
AMRU-1
Indonesia I/CDC
Chesson
Salvador I
New Guinea I/CDC
New Guinea IV/CDC
Sumatra
Palo Alto

Indonesia
Papua New Guinea
Indonesia
Papua New Guinea
El Salvador
Papua New Guinea
Papua New Guinea
Sumatra
Vietnam

North Korea
Thai III
India VII
Brazil I/CDC
Mauritania I

North Korea
Thailand
India
Brazil
Mauritania

Collins et al. [30]
Obaldia et al. [31]; Rieckmann et al. [1]
Collins et al. [32]; Schwartz et al. [3]
Collins et al. [33]; Ehrman et al. [34]
Collins et al. [36]; Contacos et al. [37]
Collins et al. [38]
a
Collins (unpublished)
b
Collins (unpublished)
Collins et al. [38]; Geiman and
Meagher [39]
Collins et al. [40]
Collins et al. [41]
c
Collins (unpublished)
Nayar et al. [42]
Collins et al. [43]

In vivo CQ
phenotype; reference
R; Collins et al. [30]
R; Obaldia et al. [31]
R; Collins et al. [32]
S; Schmidt [35]
S; Contacos et al. [37]
S; Collins (unpublished)
S; Collins (unpublished)
S; Collins (unpublished)
S; Schmidt [35]
S;
S;
S;
S;
S;

Collins (unpublished)
Collins (unpublished)
Collins (unpublished)
Nayar et al. [42]
Collins (unpublished)

NOTE. CDC, Centers for Disease Control and Prevention; R, resistant, and S, sensitive (as described in the text).
a
Isolated from an infected patient on return from New Guinea, June 1992.
b
Isolated from an oil worker in Sumatra. Patient blood was used to infect Aotus monkeys, November 1993.
c
India VII isolated from frozen blood sample from India. Adapted to Aotus monkeys, April 1995.

mainder of the samples were sequenced for exons containing codons 34, 38, and 384 (table 2). The results confirm no identifiable
association between codon mutations in pvcg10 and CQ susceptibility. All patient blood samples showed identical pvcg10 haplotypes except sample CL002, which showed a LeurPhe change at
position 384, which was similar to the AMRU-I monkey-adapted
strain. In addition, a silent mutation in codon 343 that codes for
Thr distinguished all 8 patient blood samples (ACC) from all 14
monkey-passaged isolates (ACG; data not shown).
Ancestral haplotype of CRT homologues inferred from species
of Plasmodium. Is there further evidence that points to the
lack of a role for pvcg10 codon mutations in clinically CQresistant P. vivax? The identification and sequencing of the complete coding sequence of 3 PfCRT homologues, in conjunction
with mutation data from CQ-resistant and -sensitive clones of
P. falciparum [15], can be used to infer the ancestral Plasmodium
gene haplotype listed in table 4. All CQ-resistant P. falciparum
strains from Asia, Africa, and South America analyzed thus
far show distinct pfcrt alleles that differ from this canonical,
sensitive allele by ⭓4 point mutations; amino acid changes encoded by these mutations consistently include K76T and
A220S. These mutant alleles in CQ-resistant strains of P. falciparum thus show different instances of deviations from the
haplotype, which is indicative of strong selective pressure from
CQ at this locus. By contrast, the CQ-sensitive and -resistant
strains of P. vivax show little deviation from the inferred ancestral CRT haplotype. This difference in the mutation of orthologous genes from 2 different species is supportive of a different genetic mechanism of CQR in P. vivax.

in P. falciparum was evident in the late 1950s from separate
foci in South America and Southeast Asia [46]. This history
may reflect basic differences in the genetic determinants and
molecular mechanisms of CQR in P. falciparum and P. vivax,
which is a hypothesis supported by the results described in this

Discussion

NOTE. Underlined isolates were sequenced for all exons of pvcg10. Residues
and bases in boldface represent identified polymorphic sites. CDC, Centers for
Disease Control and Prevention; R, resistant to CQ in vivo; S, sensitive to CQ;
PR, probably resistant to CQ (see table 3).

Despite comparable selection pressure from drug use, CQR
in P. vivax has been reported only since 1989, whereas CQR

Table 2. PvCG10 mutations and in vivo chloroquine (CQ) response
phenotypes of Plasmodium vivax lines from monkey and human infections.

Line or sample
Monkey adapted
Indonesia XIX
AMRU-1
Indonesia I
Chesson
Salvador I
New Guinea I/CDC
New Guinea
Sumatra
Palo Alto
Thai III
India VII
North Korea
Brazil I/CDC
Mauritania I
Patient blood samples (Papua)
CL002
CL004
CL026
CL029
CL003
CL007
CL001
CL020

Amino acid
position codon

In vivo
phenotype

34

38

384

R
R
R
S
S
S
S
S
S
S
S
S
S
S

Q
Q
Q
H
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q

P
P
P
L
P
P
P
P
P
P
P
P
P
P

L
F
—
L
L
—
—
—
—
—
—
—
—
—

R
R
R
R
PR
S
S
S

Q
Q
Q
Q
Q
Q
Q
Q

P
P
P
P
P
P
P
P

F
L
L
L
L
L
L
L
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Table 3. Eight-day in vivo chloroquine (CQ) susceptibility results
for 8 Javanese transmigrants living in Papua presenting with Plasmodium vivax malaria.
b

Sample
CL002
CL004
CL026
CL029
CL003
CL001
CL007
CL020

Parasites/mL CQ ⫹ DCQ
on day of
blood level,
d
recurrence
ng/mL

Recurrence
Parasites/mL
(day after
a
c
at day 0
CQ therapy )
4000
4720
5600
2120
5560
560
2880
600

Yes
Yes
Yes
Yes
Yes
No
No
No

(7)
(14)
(14)
(18)
(28)

360
560
200
240
280
—
—
—

In vivo
phenotype

185
115
190
145
85
—
—
—

R
R
R
R
e
PR
S
S
S

NOTE. DCQ, desethylchloroquine; PR, probably resistant to CQ; R, resistant to CQ; S, sensitive to CQ.
a
Calculated as 40 ⫻ (average no. of parasites per 200 leukocytes), assuming
8000 leukocytes/mL.
b
Presence of parasites that may be due to relapse, recrudescence, or reinfection.
c
Patients received standard CQ therapy of 25 mg base/kg body weight over
3 days (10 ⫹ 10 ⫹ 5 mg/kg doses at 24-h intervals).
d
Levels of CQ and its major metabolite, DCQ, were determined by highperformance liquid chromatography [45] from samples obtained the day recurrences were identified.
e
Classified as PR because the measured CQ blood level of 85 ng/mL was
below the formal cutoff of 100 ng/mL.

report. Although codon mutations in the pfcrt gene are central
to the CQR phenotype of P. falciparum, no codon mutations
in the pvcg10 gene could be associated with CQR in P. vivax.
These findings do not, of course, rule out the possibility of
expression level adjustments or other changes in the pvcg10
product having a potential role in CQ-resistant P. vivax.
The structure and organization of the pfcrt orthologues in
P. falciparum and P. vivax described here are highly informative,
as these 2 species are phylogenetically distant and are responsible for most malaria worldwide [47, 48]. The orthologues have
a highly interrupted gene structure, with splice junctions at 12
identical positions in the coding frame. The splice junctions
differ only by the presence in pvcg10 of an additional junction
between exons 3 and 4, which joins 2 separate exons corresponding to exon 3 of the P. falciparum gene. Notwithstanding
this conserved intron-exon structure and the high levels of identity and similarity in the encoded amino acid sequences, pfcrt
Table 4.
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and pvcg10 differ tremendously in codon usage and A/T content. These observations attest to a remarkable maintenance of
gene structure and conservation of gene function, despite the
dramatic differences in nucleotide content that have arisen since
the evolutionary divergence of P. falciparum and P. vivax.
The concept of different molecular mechanisms underlying a
common drug resistance phenotype is not an unusual scenario
among microorganisms. In bacteria, for example, despite the fact
that target similarities enable certain antimicrobial drugs to act
in a fairly uniform fashion regardless of the species, the mechanisms of resistance employed by different species of bacteria to
a single drug vary widely [49]. Plasmodium species exhibit variations in the length of time for drug resistance to develop [50],
in physiologic versus genetic resistance [51], and in the genetic
predisposition toward development of resistance [52]. Some of
these variations may reflect different features in Plasmodium
biology that allow for 1 mechanism of resistance to be favored
in 1 species but not in another. Of interest, the mechanism of
resistance to the antifolate pyrimethamine appears to be similar
among most species studied thus far: resistance in P. falciparum
and in the rodent malarias P. berghei, P. chabaudi, and P. yoelii
[53] and, more recently, in P. vivax [54] involves point mutations
in the dihydrofolate reductase drug target. Analysis of the P.
vivax cg10 gene presented here is evidence for a unique molecular
mechanism of CQR in this important species. Further progress
in the development of a continuous culture system and in genetic
analysis of P. vivax will be required to support further investigations of the CQR mechanism in this species.
Identification of pfcrt homologues in P. falciparum, P. vivax,
and Plasmodium species used as model systems for malaria
(primate and rodent) should aid investigations into the natural
function of these genes. The distantly related ssa662 gene of
D. dictyostelium also may provide useful insights into the pfcrt
homologues, although the value of such insights would necessarily be based on the manipulation of shared functional
properties in this organism. In turn, experiments directed to the
natural role of the pfcrt homologues can be expected to help
clarify the function of pfcrt itself.

Ancestral haplotype of PfCRT inferred from polymorphisms in Plasmodium species.
Amino acid position, PfCRT numbering

Species

72

74

75

76

97

220

271

326

356

371

C

M

N

K

H

A

Q

N

I

R

C/S

I/M

E/N

T

H/Q

S

E/Q

S/D/N

T/L/I

I/R/T

C
C
C
C

M
M
M
M

N
N
N
N

K
K
K
K

H
H
H
H

S
S
A
A/S

Q
Q
E
E/Q

N
N
N
N

I
I
I
I

M
M
R
R

a

P. falciparum, CQ sensitive
(canonical form)
a
P. falciparum, CQ resistant
(Old and New World forms)
P. vivax, CQ sensitive and CQ
resistant
P. knowlesi, CQ sensitive
P. berghei, CQ sensitive
Inferred ancestral haplotype

NOTE. Residues marked in boldface differ from the inferred ancestral haplotype. CQ, chloroquine.
a
From Fidock et al. [15].
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